Chip Makers Must Learn New Ways to Play "D"
By Don Scansen, EETimes (March 19, 2021)
We used to think of planar transistors in the glory days of classical Dennard scaling in two-dimensional terms. Material specifications were simplified into things like sheet resistance in ohms per square. The abstraction of the devices was was all 2-D, and most of the assumptions and the device modeling for understanding MOSFET operation for circuit design were simplified as much as possible to a pair of axes.
We might have thought of planar MOSFETs as 2-D transistors, at least until the assumptions broke down and the complexity of the device physics took off.
Eventually, planar CMOS turned to the third dimension with Intel’s TriGate and other flavors of the finFET. We called these 3-D transistors.
![]() |
E-mail This Article | ![]() |
![]() |
Printer-Friendly Page |
Related News
- "Onshoring" chip production is a red herring: the UK should double down on its competitive advantage in R&D and IP to create a secure semiconductor supply chain
- Why Must IBM Keep the Cost of Advanced Chip R&D?
- PLDA Announces QuickPCIe Lite IP, Enabling the Industry's First True "Plug and Play" PCIe IP Solution
- Cosmic Circuits Announces New IP-cores with "Ready for IBM Technology" Validations
- Chip makers must shift from fabs to systems
Breaking News
- RISC-V International Promotes Andrea Gallo to CEO
- See the 2025 Best Edge AI Processor IP at the Embedded Vision Summit
- Andes Technology Showcases RISC-V AI Leadership at RISC-V Summit Europe 2025
- RISC-V Royalty-Driven Revenue to Exceed License Revenue by 2027
- Keysom Unveils Keysom Core Explorer V1.0
Most Popular
- RISC-V International Promotes Andrea Gallo to CEO
- See the 2025 Best Edge AI Processor IP at the Embedded Vision Summit
- Andes Technology Showcases RISC-V AI Leadership at RISC-V Summit Europe 2025
- Ceva, Inc. Announces First Quarter 2025 Financial Results
- Cadence Unveils Millennium M2000 Supercomputer with NVIDIA Blackwell Systems to Transform AI-Driven Silicon, Systems and Drug Design